Carcinomas of the thyroid gland are some of the most common malignancies of the endocrine system. The causes of tumor transformation are genetic changes in genes encoding cell signaling pathways that lead to an imbalance between cell proliferation and apoptosis. Some mutations have been associated with increased tumor aggressiveness, metastatic lymph node spread, tendency to dedifferentiate, and/or reduced efficiency of radioiodine therapy. The main known genetic causes of thyroid cancer include point mutations in the BRAF, RAS, TERT, RET, and TP53 genes and the fusion genes RET/PTC, PAX8/PPAR-γ, and NTRK. Molecular genetic testing of the fine needle aspiration cytology of the thyroid tissue in the preoperative period or of the removed thyroid tissue in the postoperative period is becoming more and more common in selected institutions. Positive detection of genetic changes, thus, becomes a diagnostic and prognostic factor and a factor that determines the extent of the surgical and nonsurgical treatment. The findings of genetic research on thyroid cancer are now beginning to be applied to clinical practice. In preoperative molecular diagnostics, the aggressiveness of cancers with the most frequently occurring mutations is correlated with the extent of the planned surgical treatment (radicality of surgery, neck dissection, etc.). However, clear algorithms are not established for the majority of genetic alterations. This review aims to provide a basic overview of the findings of the most commonly occurring gene mutations in thyroid cancer and to discuss the current recommendations on the extent of surgical and biological treatment concerning preoperatively detected genetic changes.

3rd Faculty of Medicine Charles University 10000 Prague Czech Republic

Department of Molecular Endocrinology Institute of Endocrinology 11694 Prague Czech Republic

Department of Otorhinolaryngology and Maxillofacial Surgery Military University Hospital 16902 Prague Czech Republic

000      

00000naa a2200000 a 4500

001      

bmc22023820

003      

CZ-PrNML

005      

20221031095152.0

007      

ta

008      

221010s2022 sz f 000 0|eng||

009      

AR

024    7_

$a 10.3390/biomedicines10071515 $2 doi

035    __

$a (PubMed)35884820

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a sz

100    1_

$a Hlozek, Jiri $u Department of Otorhinolaryngology and Maxillofacial Surgery, Military University Hospital, 16902 Prague, Czech Republic $u Third Faculty of Medicine, Charles University, 10000 Prague, Czech Republic $1 0000000235849747

245    10

$a Genetic Changes in Thyroid Cancers and the Importance of Their Preoperative Detection in Relation to the General Treatment and Determination of the Extent of Surgical Intervention-A Review / $c J. Hlozek, B. Pekova, J. Rotnágl, R. Holý, J. Astl

520    9_

$a Carcinomas of the thyroid gland are some of the most common malignancies of the endocrine system. The causes of tumor transformation are genetic changes in genes encoding cell signaling pathways that lead to an imbalance between cell proliferation and apoptosis. Some mutations have been associated with increased tumor aggressiveness, metastatic lymph node spread, tendency to dedifferentiate, and/or reduced efficiency of radioiodine therapy. The main known genetic causes of thyroid cancer include point mutations in the BRAF, RAS, TERT, RET, and TP53 genes and the fusion genes RET/PTC, PAX8/PPAR-γ, and NTRK. Molecular genetic testing of the fine needle aspiration cytology of the thyroid tissue in the preoperative period or of the removed thyroid tissue in the postoperative period is becoming more and more common in selected institutions. Positive detection of genetic changes, thus, becomes a diagnostic and prognostic factor and a factor that determines the extent of the surgical and nonsurgical treatment. The findings of genetic research on thyroid cancer are now beginning to be applied to clinical practice. In preoperative molecular diagnostics, the aggressiveness of cancers with the most frequently occurring mutations is correlated with the extent of the planned surgical treatment (radicality of surgery, neck dissection, etc.). However, clear algorithms are not established for the majority of genetic alterations. This review aims to provide a basic overview of the findings of the most commonly occurring gene mutations in thyroid cancer and to discuss the current recommendations on the extent of surgical and biological treatment concerning preoperatively detected genetic changes.

655    _2

$a časopisecké články $7 D016428

655    _2

$a přehledy $7 D016454

700    1_

$a Pekova, Barbora $u Department of Molecular Endocrinology, Institute of Endocrinology, 11694 Prague, Czech Republic $1 000000028571164X

700    1_

$a Rotnágl, Jan $u Department of Otorhinolaryngology and Maxillofacial Surgery, Military University Hospital, 16902 Prague, Czech Republic $u Third Faculty of Medicine, Charles University, 10000 Prague, Czech Republic

700    1_

$a Holý, Richard $u Department of Otorhinolaryngology and Maxillofacial Surgery, Military University Hospital, 16902 Prague, Czech Republic $u Third Faculty of Medicine, Charles University, 10000 Prague, Czech Republic $1 0000000311126197

700    1_

$a Astl, Jaromir $u Department of Otorhinolaryngology and Maxillofacial Surgery, Military University Hospital, 16902 Prague, Czech Republic $u Third Faculty of Medicine, Charles University, 10000 Prague, Czech Republic $1 0000000280220200

773    0_

$w MED00205373 $t Biomedicines $x 2227-9059 $g Roč. 10, č. 7 (2022)

856    41

$u https://pubmed.ncbi.nlm.nih.gov/35884820 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y - $z 0

990    __

$a 20221010 $b ABA008

991    __

$a 20221031095150 $b ABA008

999    __

$a ind $b bmc $g 1854037 $s 1175108

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2022 $b 10 $c 7 $e 20220627 $i 2227-9059 $m Biomedicines $n Biomedicines $x MED00205373

GRA    __

$a MO 1012 $p Ministry of Defense of the Czech Republic

LZP    __

$a Pubmed-20221010